WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
吴氏临床与转化科学研究所
基本信息
- 批准号:10217859
- 负责人:
- 金额:$ 33.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-19 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAll of Us Research ProgramAppointmentAreaBiomedical ResearchCaringCatchment AreaClinical DataClinical ResearchClinical SciencesCollectionCommunitiesCommunity of PracticeComplexConsentConsumptionDataData CollectionData SetElectronic Health RecordFAIR principlesFutureGeneticGrowthHealth PersonnelHealth trendsHealthcareHealthcare SystemsHumanIndividualInstitutesInterviewMediatingMissouriModelingParticipantPatient CarePatient RecruitmentsPatientsPersonal Health RecordsPersonsPhenotypePhysiciansPilot ProjectsProcessProtocols documentationProviderRecruitment ActivityResearchResearch PersonnelSamplingScheduleSystemTestingThinkingTimeTranslational ResearchTranslationsUnderrepresented MinorityUnited States National Institutes of HealthUniversitiesUpdateWashingtonbasecare providerscitizen sciencecohortcomputable phenotypescostcost effectivedata warehousedigitalfollow-upgenomic datainterestmedically underserved populationnovelpatient engagementpatient portalpersonalized health carephenotypic dataprecision medicineprototyperecruitrural underservedtoolweb-based tool
项目摘要
Project Summary
This pilot project proposes to implement and evaluate a scalable digital patient engagement strategy intended
to recruit participants to the All of Us program (AoU) and harness the vast amount of electronic health record
(EHR) information available at Washington University and BJC Healthcare (WU-BJC) for precision-medicine
research. To accelerate complex genetic discovery and translation, we believe it is critical to harness existing
data quickly and efficiently and to engage research participants via digital mechanisms. Our project provides a
prototype digital precision medicine research paradigm to increase public interest in “citizen science” and
participation in AoU. By integrating digital recruitment mechanisms and EHR-based phenotyping, we can
rapidly engage, recruit, and phenotype new AoU participants in a cost-effective and timely manner.
Our approach is generalizable, adaptable, and ultimately allows for the linkage of genomic data with EHR-
derived phenotypes to accelerate biomedical research. We will test this approach in the WU-BJC system,
Missouri's largest patient care provider (> 2 million individuals annually). We will recruit active patients for AoU,
support and enable their consent, and extract and submit their EHR-derived phenotyping data to AoU.
WU-BJC uses a common, cloud-hosted EHR (Epic), with ensuing clinical data available for research purposes
via extraction and harmonization processes that populate an OMOP CDM 5.2 data repository (Research Data
Core). By recruiting patients via our shared EHR (specifically, via the integrated patient portal, MyChart), we
will quickly and efficiently create a cohort with associated and well populated clinical data sets, all with minimal
costs and participant burden. This forward-thinking “direct-to-participant” model can also be implemented to
add new online assessments and rapid data updates compared to “traditional” in-person or pre-scheduled
approaches. Based on our preliminary studies, we anticipate a majority of eligible individuals will agree to
participate in our study, to future use of their data, and to future contact. This approach will enable researchers
to effectively target emerging health trends and research needs quickly and efficiently.
We will: (1) establish a digital, community-focused patient engagement, recruitment, and consent strategy,
targeting a combination of under-represented minority, rural, and medically underserved populations in the
areas served by WU-BJC; (2) implement a phenotyping pipeline to extract, harmonize, and submit clinical data
to AoU; and (3) evaluate and optimize strategies to recruit a representative sample of participants.
We will implement a digital, direct-to-participant engagement, recruitment, and consent strategy for AoU
participation. We will demonstrate the feasibility of rapidly and inexpensively creating computable participant
phenotypes, extracted from our EHR platforms. We will evaluate and demonstrate the value of this approach to
identify opportunities for optimization and further implementation in analogous settings. Our protocols and tools
will be made available, adhering to FAIR (Findability, Accessibility, Interoperability, & Reusability) principles.
项目摘要
该试点项目建议实施和评估一个可扩展的数字化患者参与战略,
招募参与者加入我们所有人计划(AoU),并利用大量的电子健康记录,
(EHR)华盛顿大学和BJC医疗保健(WU-BJC)提供的精确医学信息
research.为了加速复杂的基因发现和翻译,我们认为利用现有的
快速有效地收集数据,并通过数字机制吸引研究参与者。我们的项目提供了
原型数字精准医学研究范式,以提高公众对“公民科学”的兴趣,
参与AoU。通过整合数字招募机制和基于EHR的表型分析,我们可以
以具有成本效益和及时的方式快速吸引,招募和表型新的AoU参与者。
我们的方法是可推广的,适应性强的,最终允许将基因组数据与EHR联系起来-
衍生表型,以加速生物医学研究。我们将在WU-BJC系统中测试这种方法,
密苏里州最大的患者护理提供商(每年超过200万人)。我们将为AoU招募活跃的患者,
支持并使他们同意,并提取和提交他们的EHR衍生表型数据给AoU。
WU-BJC使用通用的云托管EHR(Epic),确保临床数据可用于研究目的
通过提取和协调过程,填充OMOP CDM 5.2数据存储库(研究数据
核心)。通过我们共享的EHR招募患者(特别是通过集成的患者门户网站MyChart),
将快速有效地创建一个具有相关和良好填充的临床数据集的队列,所有这些都具有最小的
成本和参与者负担。这种前瞻性的“直接面向参与者”模式也可以实施,
与“传统”面对面或预先安排相比,增加新的在线评估和快速数据更新
接近。根据我们的初步研究,我们预计大多数符合条件的个人将同意
参与我们的研究,未来使用他们的数据,以及未来的联系。这种方法将使研究人员
快速有效地针对新出现的健康趋势和研究需求。
我们将:(1)建立一个数字化的、以社区为中心的患者参与、招募和同意战略,
针对代表性不足的少数民族,农村和医疗服务不足的人口,
WU-BJC服务的领域;(2)实施表型分析管道,以提取、协调和提交临床数据
评估和优化策略,以招募具有代表性的参与者样本。
我们将为AoU实施数字化、直接面向参与者的参与、招募和同意策略
参与的我们将证明快速和廉价地创建可计算参与者的可行性
表型,从我们的EHR平台提取。我们将评估和证明这种方法的价值,
确定在类似环境中优化和进一步实施的机会。我们的协议和工具
将遵循FAIR(可查找性,可访问性,互操作性和可重用性)原则。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William G. Powderly其他文献
Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031.
三甲曲沙联合甲酰四氢叶酸与甲氧苄氨嘧啶-磺胺甲恶唑治疗艾滋病患者中度至重度卡氏肺孢子虫肺炎发作:艾滋病临床试验组方案 029/031 的一项前瞻性、对照多中心研究。
- DOI:
10.1093/infdis/170.1.165 - 发表时间:
1994 - 期刊:
- 影响因子:0
- 作者:
Fred R. Sattler;Peter T. Frame;R. Davis;Larry Nichols;Brent Shelton;B. Akil;Robert P. Baughman;C. Hughlett;Walter Weiss;C. Boylen;C. V. D. Horst;John H. Black;William G. Powderly;Roy T. Steigbigel;J. Leedom;Henry Masur;Judith Feinberg - 通讯作者:
Judith Feinberg
Cyclic AMP Cyclic GMP VASCULAR tone isregulated by a variety of vasoactive mol cules : neurotransmitters
Cyclic AMP Cyclic GMP 血管张力受多种血管活性分子:神经递质调节
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry - 通讯作者:
Keith Henry
When to start antiretroviral therapy: asking the right question
何时开始抗逆转录病毒治疗:提出正确的问题
- DOI:
10.2217/fvl.11.26 - 发表时间:
2011 - 期刊:
- 影响因子:3.1
- 作者:
William G. Powderly - 通讯作者:
William G. Powderly
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
先前奈非那韦治疗失败的患者对含利托那韦-沙奎那韦疗法的病毒学反应。
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:0
- 作者:
P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry - 通讯作者:
Keith Henry
Efficacy of Infliximab, Abatacept, and Cenicriviroc for the Treatment of Adults Hospitalized with COVID-19 Pneumonia
英夫利昔单抗、阿巴西普和西尼立韦罗治疗因 COVID-19 肺炎住院的成人的疗效
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:8.4
- 作者:
Dan;Jianqiao Wang;Kevin J. Anstrom;Lisa M. LaVange;Jun Wen;Samuel A. Bozzette;William G. Powderly - 通讯作者:
William G. Powderly
William G. Powderly的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William G. Powderly', 18)}}的其他基金
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
- 批准号:
10827727 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
- 批准号:
10700256 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
华盛顿大学临床与转化科学研究所
- 批准号:
10321102 - 财政年份:2017
- 资助金额:
$ 33.96万 - 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
- 批准号:
10556449 - 财政年份:2017
- 资助金额:
$ 33.96万 - 项目类别:
Washington University Institute of Clinical Translational Sciences
华盛顿大学临床转化科学研究所
- 批准号:
9889200 - 财政年份:2017
- 资助金额:
$ 33.96万 - 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
- 批准号:
10598597 - 财政年份:2017
- 资助金额:
$ 33.96万 - 项目类别:
Rosiglitazone & Exercise Training: Effects on HIV-Infected People
罗格列酮
- 批准号:
6971952 - 财政年份:2004
- 资助金额:
$ 33.96万 - 项目类别:
STUDY OF ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS
HIV 感染者每周一次阿仑膦酸钠的研究
- 批准号:
6971984 - 财政年份:2004
- 资助金额:
$ 33.96万 - 项目类别:
WU 122: EVALUATE METABOLIC EFFECTS OF DISCONTINUATION OF ANTIRETROVIRAL THERAPY
WU 122:评估停止抗逆转录病毒治疗的代谢影响
- 批准号:
6971971 - 财政年份:2004
- 资助金额:
$ 33.96万 - 项目类别:
相似海外基金
The Illinois Precision Medicine Consortium (IPMC) All of Us Research Program Site
伊利诺伊州精准医学联盟 (IPMC) All of Us 研究计划网站
- 批准号:
10872859 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Nutrition for Precision Health, powered by the All of Us Research Program: Research Coordinating Center
精准健康营养,由“我们所有人研究计划”提供支持:研究协调中心
- 批准号:
10874354 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
All of Us Research Program Trans-America Consortium of the HCSRN
我们所有人研究计划 HCSRN 泛美联盟
- 批准号:
10871074 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
All of Us Research Program Heartland Consortium (AoURP-HC)
我们所有人研究计划中心联盟 (AoURP-HC)
- 批准号:
10871732 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
DARSaW: Developing, Assessing, and Refining Synthetic Sampling Weights to Improve Generalizability of the All of Us Research Program Data
DARSaW:开发、评估和细化合成采样权重,以提高我们所有人研究计划数据的普遍性
- 批准号:
10796237 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Engaging Diverse Stakeholders in Genomic/Precision Medicine Research: The All of Us Research Program Engagement Core
让不同的利益相关者参与基因组/精准医学研究:我们所有人研究计划的参与核心
- 批准号:
10789515 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Investigation of the social context and physical environment on cardiovascular disease disparities in the All of Us Research Program
“我们所有人研究计划”中心血管疾病差异的社会背景和物理环境调查
- 批准号:
10798725 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
The Participant Center: Empowering All of Us Research Program participation across the United States
参与者中心:增强我们所有人参与美国各地研究计划的能力
- 批准号:
10774158 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Nutrition for Precision Health, powered by the All of Us Research Program: Research Coordinating Center
精准健康营养,由“我们所有人研究计划”提供支持:研究协调中心
- 批准号:
10757488 - 财政年份:2023
- 资助金额:
$ 33.96万 - 项目类别:
Multilevel analyses of oral health conditions among older adults in the All of Us Research Program
“我们所有人研究计划”中老年人口腔健康状况的多层次分析
- 批准号:
10658463 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:














{{item.name}}会员




